Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with ...

8 September 2026 · By · Wire by Fusion42

Published

8 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at ir.intelliatx.com →

◆ Verified

Fusion42 · 8 September 2026 · Fusion42 review

The FDA has accepted Intellia Therapeutics' Biologics License Application for lonvo-z, their in vivo CRISPR-based therapy for hereditary angioedema, granting it Priority Review with a target decision date of March 10, 2027. This therapy aims to be the first one-time treatment of its kind, backed by strong Phase 3 trial results showing significant reduction in attacks.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

The FDA’s Priority Review for lonvo-z clears a direct path to lead the gene editing space in rare disease treatment. You selling HAE or rare genetic therapies now face a new benchmark for one-time curative potential.

◆ Coverage

1 source · 8 Sep 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalgene-editingcrisperbiologicsphase-3-trials